Autor(es)

Juliato, Cassia R. T. ^[1] ; Stahlschmidt, Paulo ^[1] ; Fernandes, Arlete ^[1] ; Monteiro, Ilza ^[1] ; Bahamondes, Luis ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Contraception; v. 98, n. 3, p. 252-254, SEP 2018.
• Citações Web of Science: 2

Resumo

Objective: To assess the clinical performance (pregnancy and occurrence of pelvic infection) of the levonorgestrel 52-mg intrauterine system (LNG IUS) in solid organ transplant recipients. Study design: We performed a retrospective chart review of all patients seen in the Family Planning Clinic at the University of Campinas Department of Obstetrics and Gynecology from 2007 to 2017 to identify women with solid organ transplantation using immunosuppression who received an LNG IUS. Our routine clinical practice for such patients is to perform initial follow-up 40-60 days after placement and then every 12 months. We analyzed women's sociodemographic characteristics, duration of use of the LNG IUS, continuation and discontinuation reasons, and complications. Results: Of the 23 women evaluated, 21 had kidney transplantation and 2 had liver transplantation. One woman received an LNG IUS prior to solid organ implantation (1.7 years, renal transplant). The 22 other women received the LNG IUS a median of 6.3 years (interquartile {[}IQ25-75] range 1.7-15 years). Seventeen (74%) women primarily used the LNG IUS for contraception; the other 6 desired the LNG IUS for contraception and heavy menstrual bleeding (HMB) treatment. We observed no cases of pregnancy or pelvic infection. Over the median follow-up time of 49.3 months (IQ(25-75) 15-80 months), 7 women used the same IUS for more than 60 months and 8 women received a second IUS. Conclusions: Due to the fact that no pregnancies or pelvic infections were observed in this case series, we concluded that the LNG IUS is an option for transplanted women for contraception and for HMB treatment. (C) 2018 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 15/20504-9 - Manifestações clínicas de usuárias de contraceptivos de somente progestogênios
• Beneficiário: Luis Guillermo Bahamondes
• Modalidade de apoio: Auxílio à Pesquisa - Temático